IMMORNA

What this means for you

Not registered yet, but its 23 May 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

97424017

Mark type

Stylized text

Filed

23 May 2022

Published for opposition

31 Oct 2023

Attorney of record

Keith Toms, Esq.

Goods and services

• Class 001 — Chemicals: Reagents for scientific, research, and medical research use; chemical reagents other than for medical purposes; diagnostic reagents for clinical or medical laboratory use; mRNA reagents for scientific, research, and medical research use; reagents comprised of nanoparticles for scientific, research, and medical research use; reagents, comprised of capsids for scientific, research, and medical research use
• Class 005 — Pharmaceuticals: Messenger RNA (mRNA) pharmaceutical and biopharmaceutical preparations for use in the treatment of oncological diseases and disorders, infectious diseases, autoimmune and genetic diseases and disorders, and for use in medical cosmetology; messenger RNA (mRNA) pharmaceutical and biopharmaceutical preparations for vaccines; Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; Pharmaceutical preparations and substances for the treatment of infectious diseases; vaccines; pharmaceutical preparations and substances for the treatment of autoimmune diseases and disorders, autoimmune deficiency; pharmaceutical preparation and substances for the treatment of genetic disorders; pharmaceutical preparations and substances for use in medical cosmetology; diagnostic biomarker reagents for medical purposes; protein arrays for medical diagnosis purposes; diagnostic preparations for medical purposes for detecting the presence of tumors, infectious diseases, genetic disorders and autoimmune disorders and conditions; drug delivery agents in the form of polymer and lipid nanoparticles for delivery of mRNA being a pharmaceutical preparation; drug delivery agents in the form of nanoparticles and capsids for delivery for a wide variety of therapeutic agents
• Class 040 — Treatment of materials: Manufacture of nanoparticles and capsids for use in connection with mRNA-based therapeutics for others
• Class 042 — Scientific and technological services: Research and development of messenger RNA (mRNA) biotechnologies; Research and development services in the field of biologics, including but not limited to mRNA, RNA, DNA, antibodies, vaccines, and peptides; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostic services for scientific research purposes, and pharmacogenetics; conducting research and clinical trials for others in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostic services for scientific research purposes, and pharmacogenetics; Scientific research, namely, mRNA synthesis, purification and testing

Owner

• Immorna Biotherapeutics Inc., Morrisville, NC, US
• Immorna Biotherapeutics Inc., Morrisville, NC, US

Prosecution history

• 23 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 22 Dec 2025 — SOU EXTENSION 4 GRANTED
• 22 Dec 2025 — SOU EXTENSION 4 FILED
• 22 Dec 2025 — SOU TEAS EXTENSION RECEIVED
• 25 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 24 Jun 2025 — SOU EXTENSION 3 GRANTED
• 24 Jun 2025 — SOU EXTENSION 3 FILED
• 24 Jun 2025 — SOU TEAS EXTENSION RECEIVED
• 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 20 Dec 2024 — SOU EXTENSION 2 GRANTED
• 20 Dec 2024 — SOU EXTENSION 2 FILED
• 20 Dec 2024 — SOU TEAS EXTENSION RECEIVED
• 25 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 25 Jun 2024 — SOU EXTENSION 1 GRANTED
• 25 Jun 2024 — SOU EXTENSION 1 FILED